Five-Year Follow-Up Data for SPRYCELÂ® (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant or Intolerant to GleevecÂ®*